IMV Inc. is a clinical-stage immuno-oncology company that develops therapies for solid and hematological cancers using its immune-educating technology platform, DPX. Its lead drug candidate, maveropepimut-S, is in Phase II clinical trials for various cancers, and it also develops therapies for infectious diseases. The company was founded in 2000 and is headquartered in Dartmouth, Canada.